Inflammasome Inhibitor Moving Through the Pipeline

Show Description +

Dr. Shen reviews data from the phase 2 clinical trial of the K8 implant (Inflammasome Therapeutics) for patients with geographic atrophy (GA). The researchrs noted a 54% reduction in GA lesion growth rate at 6 months.

Posted: 10/15/2026

Keywords:

•

fluocinolone acetonide implant

•

Inflammasome Therapeutics

•

Clinical Trials

•

Geographic Atrophy (GA)

•

Age-Related Macular Degeneration (AMD)

•

Lesions

•

retina-meeting-recap

•

Retina Subspecialty Day

Up Next

Name: Inflammasome Inhibitor Moving Through the Pipeline
Uploaded: 2026-10-15T19:21:40+00:00
Description: Dr. Shen reviews data from the phase 2 clinical trial of the K8 implant (Inflammasome Therapeutics) for patients with geographic atrophy (GA). The researchrs noted a 54% reduction in GA lesion growth rate at 6 months.